MARKET

SPRY

SPRY

ARS Pharms
NASDAQ
8.00
-0.05
-0.62%
After Hours: 8.13 +0.13 +1.63% 19:11 04/13 EDT
OPEN
8.00
PREV CLOSE
8.05
HIGH
8.30
LOW
8.00
VOLUME
854.40K
TURNOVER
--
52 WEEK HIGH
18.90
52 WEEK LOW
6.66
MARKET CAP
794.38M
P/E (TTM)
-4.6033
1D
5D
1M
3M
1Y
5Y
1D
Top and lowest-rated small-cap stocks heading into earnings
Seeking Alpha · 14h ago
Weekly Report: what happened at SPRY last week (0406-0410)?
Weekly Report · 17h ago
ARS PHARMACEUTICALS INC <SPRY.O>: NORTHLAND CAPITAL INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $25
Reuters · 4d ago
ARS Pharmaceuticals initiated with an Outperform at Northland
TipRanks · 4d ago
Northland starts disruptor ARS Pharmaceuticals with an Outperform
TipRanks · 4d ago
U.S. RESEARCH ROUNDUP-Comstock Resources, Trustmark, Viasat
Reuters · 4d ago
Weekly Report: what happened at SPRY last week (0330-0403)?
Weekly Report · 04/06 10:40
Ars Pharmaceuticals Earnings Call Highlights Neffy’s Early Traction
TipRanks · 04/03 00:29
More
About SPRY
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.

Webull offers ARS Pharmaceuticals Inc stock information, including NASDAQ: SPRY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPRY stock methods without spending real money on the virtual paper trading platform.